Pfizer gets unexpected boost from Covid vaccine and pill
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to fend off criticism from an activist investor that has argued the company squandered its pandemic gains and needs a new path forward.
Pfizer harnesses COVID fluctuations to clinch Q4 gains as RSV vaccine sales plummet
After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.” | The company benefited from higher-than-expected sales of COVID vaccine Comirnaty and antiviral Paxlovid,
Pfizer shares, which had risen Tuesday morning after improved demand for the Covid vaccine, dropped 2.3% after Kennedy's ...
The Illinois Labor Relations Board has twice ruled that the city violated employees' collective bargaining rights by failing ...
Other fact-checking organizations have debunked the claim; Reuters and AFP have also fact-checked similar claims that circulated in 2022 and 2023 ...
"Pfizer just released its list of side effects of its COVID-19 vaccine," multiple Facebook posts said Jan. 26 and 27. The posts included a purported list of 46 Pfizer-BioNtech COVID-19 vaccine side ...
Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...
Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...
Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...
The bill would implement a moratorium for a decade. “I am not against vaccination in any way,” the freshman lawmaker said.
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback